Clinical study report for plavix Case Example | Topics and Well Written Essays - 3750 words

Clinical report for clopidogrel bisulfate - Case Study Exampleat least an issue of atherothrombotic event like heart malady, crack as well as those diagnosed with peripheral arterial diseases characterized by problems with blood flowing into arteries especially in the leg region. This medicine is also prescribed for patients diagnosed with acute coronary syndrome (ACS) and those with arterial fibrillation (AF) characterized by fast and strong heartbeats (Dickie, Jennifer, and Lesley 34).Platelets are responsible for the clotting of blood whenever it is necessary for example, when one has a cut and in doing so prevents father bleeding and hemorrhage. In the event that arteries are narrowed by plagues, the body reacts by aggregating unneurotic and they may rapture and further increase narrowing of these vessels, which is, likely to increase the chance of heart attack, guesswork and other circulatory disorders. This medicine acts by reducing the chances of these occurrences by p reventing the coagulation in the first place.clopidogrel bisulfate acts by irreversibly binding to the P2Y12 receptors on platelets and preventing Adenosine diphosphate (ADP) from activating platelets, which form clots. Drug belongs to the group of drugs called P2Y12 inhibitors and is similar to the drug Ticlopidine (Ticlid) in its chemical structure and mechanism of action. The only difference is that Clopidogrel bisulfates do not cause effective decline in the white blood cell count as seen in patients on Ticlopidine indeed there is no need for regular tests to determine white blood cell counts.Plavix is employ to prevent the risk of heart disease and stroke in patients who have had a recent episode of heart attack, stroke and narrowed arteries as well as those suffering from peripheral vascular disease characterized by pain in the leg, which could be disabling. The US Food and Drug Association (FDA) approved this drug in 1997.This drug is used in prevention of atherothrombotic events like myocardial infarction (MI), Stroke and vascular death in patients with